Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-088584
Filing Date
2024-07-31
Accepted
2024-07-31 16:14:11
Documents
47
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q bmea-20240630.htm   iXBRL 10-Q 1914258
2 EX-31.1 bmea-ex31_1.htm EX-31.1 16179
3 EX-31.2 bmea-ex31_2.htm EX-31.2 16189
4 EX-32.1 bmea-ex32_1.htm EX-32.1 8717
5 EX-32.2 bmea-ex32_2.htm EX-32.2 8633
  Complete submission text file 0000950170-24-088584.txt   5271421

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT bmea-20240630.xsd EX-101.SCH 673823
50 EXTRACTED XBRL INSTANCE DOCUMENT bmea-20240630_htm.xml XML 565845
Mailing Address 900 MIDDLEFIELD ROAD 4TH FLOOR REDWOOD CITY CA 94063
Business Address 900 MIDDLEFIELD ROAD 4TH FLOOR REDWOOD CITY CA 94063 (650) 980-9099
Biomea Fusion, Inc. (Filer) CIK: 0001840439 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40335 | Film No.: 241162118
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)